iCardio.ai Joins Butterfly Garden to Deploy Its Cardiac AI Suite on Butterfly Network's Imaging Platform

iCardio.ai's AI suite (pending FDA 510(k) clearance) includes instant automated interpretation of dozens of measurements of the heart, valvular disease detection, and image quality assessment. With this partnership, iCardio.ai will be compatible with Butterfly's leading imaging platform.

LOS ANGELES, CA / ACCESSWIRE / November 14, 2023 / iCardio.ai, a developer of deep learning algorithms for ultrasound images, today announced it has joined Butterfly Garden, an artificial intelligence (AI) Marketplace launched by Butterfly Network, Inc, ("Butterfly") (NYSE:BFLY) a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software. Under the agreement, iCardio.ai plans to develop and deploy its suite of cardiac ultrasound AI tools for use with Butterfly's single-probe, whole-body handheld ultrasound system, subject to applicable approvals and authorizations.

The iCardio.ai software, which is currently pending FDA 510(k) clearance, provides a preliminary echocardiographic (echo) report that automates dozens of critical measurements of the heart, detects valvular disease such as aortic stenosis, provides image quality assessment, and more. Through this partnership, iCardio.ai and Butterfly Network aim to make these tools accessible to Butterfly's user base of more than 100,000 providers, enabling them to take a simplified echo examination of the heart with a Butterfly probe and instantly produce a fully automated echo report. Making this AI compatible with the Butterfly probe introduces immense clinical value, with the potential to impact millions of patients globally by empowering more accessible, timely, and accurate cardiac assessment.

In August 2023, Butterfly Network launched Butterfly Garden, allowing third-party developers access to its proprietary SDK and APIs to build new AI applications that work in conjunction with Butterfly's imaging platform, bringing with it access to the largest point-of-care ultrasound customer base. iCardio.ai, with its suite of FDA-pending artificial intelligence software, was an ideal match for the program.

"iCardio.ai brings its technology to market by partnering with PACs and Ultrasound vendors, and we are thrilled to be partnering with Butterfly Network. By combining our technologies, we are empowering the Butterfly probe with iCardio.ai's built-in artificial intelligence software. Our ambition aims to eventually put into the hands of every person with a Butterfly device the power of a super-human AI cardiologist." - Joseph Sokol, CEO & Founder of iCardio.ai

Darius Shahida, Butterfly Network's Chief Strategy Officer & Chief Business Development Officer, added, "The inclusion of iCardio.ai's powerful cardiac ultrasound AI tools in the Butterfly Garden further edifies our goal of building the leading destination for AI in ultrasound. iCardio.ai's complementary technology will not only bring additional capabilities to our Butterfly customers, but also continue to make it easier for healthcare practitioners to use ultrasound wherever they may be."

About iCardio.ai

iCardio.ai is a Los Angeles-based AI startup that develops machine learning and deep learning algorithms for the analysis of ultrasound applications, with a specific focus on transthoracic echocardiography (echo). iCardio.ai's core artificial intelligence was trained on its proprietary database of over +200M ultrasound images, making it one of the largest-scale AI-based medical imaging products in the world. iCardio.ai is currently pending FDA 510(k) clearance for market authorization in the United States. To bring its AI algorithms for ultrasound, iCardio.ai has partnered with some of the largest players in the industry and now has proudly partnered with Butterfly Network.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single-proble, whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy to use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country.

Contact Information

Joseph Sokol
Chief Executive Officer
humans@icardio.ai

Darius Shahida
Chief Strategy & Business Development Officer
dshahida@butterflynetinc.com

Liz Learned
Head of Corporate Communications
media@butterflynetwork.com

SOURCE: iCardio.ai